Media

Kyowa Kirin and GENESIS Pharma announce new partnership for rare disease medicines portfolio in Greece, Cyprus and Malta

December 20, 2022 – Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin), a Japan-based global specialty pharmaceutical company, and GENESIS Pharma, a leading regional biopharma company operating in the broader region of Southeast Europe, have announced a commercialization agreement for two new orphan-designated medicines in Greece, Cyprus and Malta. Under the terms of the agreement, GENESIS Pharma will commercialize Burosumab for the treatment of X-Linked Hypophosphataemia (XLH) and Tumour-Induced Osteomalacia (TIO) and Mogamulizumab for two subtypes of cutaneous T-cell lymphoma (CTCL), a rare non-Hodgkin lymphoma, upon local market approval.

GENESIS Pharma Announces Expansion of Commercialization Agreement with Incyte

The expanded agreement includes two new orphan-designated cancer medicines in 11 markets in Southeast Europe  

25 October 2022 –GENESIS Pharma, a leading regional biopharma company operating in the broader region of Southeast Europe, today announced an expansion of the exclusive supply and distribution agreement with Incyte Biosciences International Sàrl, continuing their successful six year collaboration for ponatinib. The expanded agreement includes the commercialization of two new, orphan-designated, cancer medicines as well as the geographical extension of the agreement to include 11 markets: Greece, Cyprus, Croatia, Slovenia, Malta, Serbia, North Macedonia, Bosnia and Herzegovina, Kosovo, Albania and Montenegro.

At GENESIS Pharma, we relentlessly assess new opportunities throughout the world, so as to fulfill our mission to bring innovative & effective treatments medicines closer to those who need them, no matter how many or few they are, in a continuous effort to make their lives better, more functional, with more quality and hope.

20 October 2021 –GENESIS Pharma, a leading regional biopharma company operating in the broader region of Southeast Europe, announced their exclusive agreement with Seagen Inc, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for the commercialization of an innovative, new cancer medicine in Greece, Cyprus and Malta, to treat patients with HER2 positive locally advanced or metastatic breast cancer.

29 September 2021 – GENESIS Pharma, a leading regional biopharma company operating in the broader region of South East Europe, announced their exclusive agreement with Jazz Pharmaceuticals, a global biopharmaceutical company dedicated to developing life-changing medicines for serious diseases, for the commercialization of a cancer medicine in Greece, Cyprus and Malta, for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Alnylam Pharmaceuticals and GENESIS Pharma partner to commercialize patisiran in South East Europe

Migalastat is the first oral treatment as well as the first precision medicine for Fabry disease.

[Athens, Tuesday 12 March 2019] GENESIS Pharma, a leading regional biopharma company operating in the broader region of Southeast Europe, announces that Amicus Therapeutics, a biotechnology company at the forefront of rare and orphan diseases, has granted the company exclusive rights to commercialize migalastat in Greece, Cyprus, Romania and Bulgaria. The European Commission granted full approval of migalastat in May 2016. Under the terms of the agreement, GENESIS Pharma will be responsible for the sales and marketing, medical affairs, regulatory and reimbursement support for migalastat in the above markets.